drugset / Trial / NCT05429476

EXtending the Time Window for Thrombolysis in Posterior Circulation Stroke Without Early CT Signs

NCT05429476

RandomizedParallel-groupDouble-blindTreatment

Summary

The primary hypothesis being tested in this trial is that ischemic stroke patients in posterior circulation at 4.5 - 24 hours post onset of stroke will have improved clinical outcomes when given intravenous tissue plasminogen activator (tPA) compared to standard care.

Timeline

Start
2022-08-17
Primary completion
2024-08-15
Completion
2024-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 0.9 mg/kg

Indications